Literature DB >> 15681822

Polymers of Z alpha1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo.

Ravi Mahadeva1, Carl Atkinson, Zhenjun Li, Susan Stewart, Sabina Janciauskiene, Diane G Kelley, Jasvir Parmar, Rebecca Pitman, Steven D Shapiro, David A Lomas.   

Abstract

The molecular mechanisms that cause emphysema are complex but most theories suggest that an excess of proteinases is a crucial requirement. This paradigm is exemplified by severe deficiency of the key anti-elastase within the lung: alpha(1)-antitrypsin. The Z mutant of alpha(1)-antitrypsin has a point mutation Glu342Lys in the hinge region of the molecule that renders it prone to intermolecular linkage and loop-sheet polymerization. Polymers of Z alpha(1)-antitrypsin aggregate within the liver leading to juvenile liver cirrhosis and the resultant plasma deficiency predisposes to premature emphysema. We show here that polymeric alpha(1)-anti-trypsin co-localizes with neutrophils in the alveoli of individuals with Z alpha(1)-antitrypsin-related emphysema. The significance of this finding is underscored by the excess of neutrophils in these individuals and the demonstration that polymers cause an influx of neutrophils when instilled into murine lungs. Polymers exert their effect directly on neutrophils rather than via inflammatory cytokines. These data provide an explanation for the accelerated tissue destruction that is characteristic of Z alpha(1)-antitrypsin-related emphysema. The transition of native Z alpha(1)-antitrypsin to polymers inactivates its anti-proteinase function, and also converts it to a proinflammatory stimulus. These findings may also explain the progression of emphysema in some individuals despite alpha(1)-antitrypsin replacement therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15681822      PMCID: PMC3278851          DOI: 10.1016/s0002-9440(10)62261-4

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  50 in total

1.  The electrophoretic α1-globulin pattern of serum in α1-antitrypsin deficiency. 1963.

Authors:  Carl-Bertil Laurell; Sten Eriksson
Journal:  COPD       Date:  2013-03       Impact factor: 2.409

2.  Studies in alpha 1-antitrypsin deficiency.

Authors:  S Eriksson
Journal:  Acta Med Scand Suppl       Date:  1965

3.  Cirrhosis associated with alpha-1-antitrypsin deficiency: a previously unrecognized inherited disorder.

Authors:  H L Sharp; R A Bridges; W Krivit; E F Freier
Journal:  J Lab Clin Med       Date:  1969-06

Review 4.  The Pi polymorphism: genetic, biochemical, and clinical aspects of human alpha 1-antitrypsin.

Authors:  M K Fagerhol; D W Cox
Journal:  Adv Hum Genet       Date:  1981

5.  Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants.

Authors:  T Sveger
Journal:  N Engl J Med       Date:  1976-06-10       Impact factor: 91.245

6.  Antielastases of the human alveolar structures. Implications for the protease-antiprotease theory of emphysema.

Authors:  J E Gadek; G A Fells; R L Zimmerman; S I Rennard; R G Crystal
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

7.  Experimental emphysema induced with purified human neutrophil elastase: tissue localization of the instilled protease.

Authors:  A Janoff; B Sloan; G Weinbaum; V Damiano; R A Sandhaus; J Elias; P Kimbel
Journal:  Am Rev Respir Dis       Date:  1977-03

8.  Structural evidence for methionine at the reactive site of human alpha-1-proteinase inhibitor.

Authors:  D Johnson; J Travis
Journal:  J Biol Chem       Date:  1978-10-25       Impact factor: 5.157

9.  The nature of small-airway obstruction in chronic obstructive pulmonary disease.

Authors:  James C Hogg; Fanny Chu; Soraya Utokaparch; Ryan Woods; W Mark Elliott; Liliana Buzatu; Ruben M Cherniack; Robert M Rogers; Frank C Sciurba; Harvey O Coxson; Peter D Paré
Journal:  N Engl J Med       Date:  2004-06-24       Impact factor: 91.245

Review 10.  Chronic obstructive pulmonary disease: molecular and cellular mechanisms.

Authors:  P J Barnes; S D Shapiro; R A Pauwels
Journal:  Eur Respir J       Date:  2003-10       Impact factor: 16.671

View more
  62 in total

Review 1.  Lung disease associated with alpha1-antitrypsin deficiency.

Authors:  Rubin M Tuder; Sabina M Janciauskiene; Irina Petrache
Journal:  Proc Am Thorac Soc       Date:  2010-11

Review 2.  Protein misfolding and the serpinopathies.

Authors:  Didier Belorgey; Peter Hägglöf; Susanna Karlsson-Li; David A Lomas
Journal:  Prion       Date:  2007-01-06       Impact factor: 3.931

3.  Rationale and Design of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis Study. Alpha-1 Protocol.

Authors:  Charlie Strange; Robert M Senior; Frank Sciurba; Scott O'Neal; Alison Morris; Stephen R Wisniewski; Russell Bowler; Harry S Hochheiser; Michael J Becich; Yingze Zhang; Joseph K Leader; Barbara A Methé; Naftali Kaminski; Robert A Sandhaus
Journal:  Ann Am Thorac Soc       Date:  2015-10

Review 4.  Risk of Lung Disease in PI MZ Heterozygotes. Current Status and Future Research Directions.

Authors:  Edwin K Silverman
Journal:  Ann Am Thorac Soc       Date:  2016-08

5.  New Findings in PiZZ alpha1-antitrypsin deficiency-related panniculitis. Demonstration of skin polymers and high dosing requirements of intravenous augmentation therapy.

Authors:  B Gross; M Grebe; M Wencker; J K Stoller; L M Bjursten; S Janciauskiene
Journal:  Dermatology       Date:  2009-02-16       Impact factor: 5.366

6.  Immunomodulation by alpha(1)-proteinase inhibitor: lack of chemotactic effects of recombinant human alpha(1)-proteinase inhibitor from yeast on human peripheral blood granulocytes.

Authors:  Birgit Mosheimer; Reinhard Alzner; Christian J Wiedermann
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2007-12-03       Impact factor: 4.291

Review 7.  Roles for proteinases in the pathogenesis of chronic obstructive pulmonary disease.

Authors:  Caroline A Owen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

8.  Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency.

Authors:  Irina Petrache; Joud Hajjar; Michael Campos
Journal:  Biologics       Date:  2009-07-13

9.  Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency.

Authors:  Caitriona McLean; Catherine M Greene; Noel G McElvaney
Journal:  Biologics       Date:  2009-07-13

10.  Oxidized {alpha}1-antitrypsin stimulates the release of monocyte chemotactic protein-1 from lung epithelial cells: potential role in emphysema.

Authors:  Zhenjun Li; Sam Alam; Jicun Wang; Caroline S Sandstrom; Sabina Janciauskiene; Ravi Mahadeva
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-06-12       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.